Apimeds Pharmaceuticals US Net Income

Apimeds Pharmaceuticals US posts a net income of $-58M as of June 2026. That compares with $-3.7M in the prior-year period — down 1468.4% year over year. That is below the sector sector average of $96M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Apimeds Pharmaceuticals US's net income was $-3.7M. The latest reading is $-58M — a 1468.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a net income near $96M is typical. Apimeds Pharmaceuticals US's $-58M is lower that level. That is roughly 160.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Apimeds Pharmaceuticals US's financial statement story. At $-58M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for APUS's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $96M), and (3) consistency with growth and profitability. This page covers the first two; Apimeds Pharmaceuticals US's other metric pages and overview cover the third.